Jennifer Doudna, Intellia co-founder (Susan Walsh/AP Images)

Ex­pand­ed In­tel­lia CRISPR da­ta set up show­down with Pfiz­er, Io­n­is and Al­ny­lam in not-so-rare dis­ease

Eight months af­ter de­liv­er­ing land­mark re­sults with one of the first CRISPR clin­i­cal tri­als of its kind, In­tel­lia an­nounced the ex­per­i­men­tal ther­a­py held up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.